According to the results:
-- The AMDL-ELISA DR-70 (FDP) test showed strong clinical performance
with a sensitivity of 91% and a specificity of 93% in testing
conducted on patients with hepatocellular, cholangiocellular,
pancreatic, colorectal, stomach and oesophagus cancers.
-- The test reliably differs between patients with cancer of the
gastrointestinal tract or the hepatobilary system and healthy
patients; therefore showing promise as a useful cancer detection tool
in clinical practice.
-- The study also found an association between the quantitative DR-70
value and the stage of the cancer in patients tested which suggests
the AMDL-ELISA DR-70 (FDP) test can also be used as a prognostic
factor in cancer monitoring.
About AMDL: Headquartered in Tustin, CA with operations in Shenzhen,
Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade
Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical
company devoted to the research, development, manufacturing, and marketing
of diagnostic, pharmaceutical, nutritional supplement, and cosmetic
products. The company employs approximately 320 people in the U.S. and
China. The AMDL ELISA DR-70 (FDP) cancer diagnostic test was cleared to
market by the US FDA on July 13, 2008 and the Company has 4 additional
pharmaceutical and diagnostic products under review by various regulatory
authorities. For additional information on AMDL and its products visit the
company's website at http://www.amdl.com or call +1 (714)505-4460.
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved